FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224302114> ?p ?o ?g. }

• W4224302114 abstract "Abstract Background In the phase 2/3 BLAZE-1 trial, bamlanivimab and etesevimab together reduced coronavirus disease 2019 (COVID-19)–related hospitalizations and any-cause mortality in ambulatory patients. Herein, we assess the impact of bamlanivimab and etesevimab treatment on the severity and length of symptoms and health outcomes among patients at increased risk for severe COVID-19. Methods In the phase 3 portion of BLAZE-1 (NCT04427501), symptomatic patients with increased risk for severe COVID-19 were randomized (2:1) to a single infusion of 700 mg bamlanivimab and 1400 mg etesevimab or placebo. Hospitalization events, vital signs, and symptomatology were monitored throughout the trial. Results Overall, 769 patients were randomized to bamlanivimab and etesevimab together (n = 511) or placebo (n = 258). The time to sustained symptom resolution was significantly shorter among patients who received bamlanivimab and etesevimab compared with placebo (8 vs 10 days; P &lt; .01). The median time to first sustained symptom resolution of body aches and pain, chills, fatigue, feeling feverish, headache, and shortness of breath was significantly different in patients receiving bamlanivimab and etesevimab compared to placebo (P &lt; .05). The proportion of patients who experienced COVID-19–related hospitalization by day 29 was significantly reduced among the bamlanivimab and etesevimab group compared with placebo (0.8% vs 5.4%; P &lt; .01). The mean duration of hospital stay was numerically shorter among patients who received bamlanivimab and etesevimab (7.3 vs 13.5 days; P = .16), with fewer intensive care admissions. Conclusions Patients receiving bamlanivimab and etesevimab together resolved their symptoms more rapidly than those receiving placebo. Bamlanivimab and etesevimab treatment was associated with reduced rates of hospitalizations and shorter hospital stays. Clinical Trials Registration NCT04427501." @default.
• W4224302114 created "2022-04-26" @default.
• W4224302114 creator A5014291037 @default.
• W4224302114 creator A5025715364 @default.
• W4224302114 creator A5025877100 @default.
• W4224302114 creator A5032261051 @default.
• W4224302114 creator A5033387742 @default.
• W4224302114 creator A5041687666 @default.
• W4224302114 creator A5046856654 @default.
• W4224302114 creator A5047777011 @default.
• W4224302114 creator A5064722914 @default.
• W4224302114 creator A5082680257 @default.
• W4224302114 creator A5083402039 @default.
• W4224302114 date "2022-04-07" @default.
• W4224302114 modified "2023-10-02" @default.
• W4224302114 title "Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial" @default.
• W4224302114 cites W3008028633 @default.
• W4224302114 cites W3008827533 @default.
• W4224302114 cites W3020773974 @default.
• W4224302114 cites W3024193040 @default.
• W4224302114 cites W3041608683 @default.
• W4224302114 cites W3043192034 @default.
• W4224302114 cites W3111255098 @default.
• W4224302114 cites W3111431752 @default.
• W4224302114 cites W3125712166 @default.
• W4224302114 cites W3158276912 @default.
• W4224302114 cites W3180810349 @default.
• W4224302114 cites W3184339862 @default.
• W4224302114 cites W3197788122 @default.
• W4224302114 cites W3209238777 @default.
• W4224302114 cites W4205483821 @default.
• W4224302114 cites W4212988737 @default.
• W4224302114 cites W4226148899 @default.
• W4224302114 doi "https://doi.org/10.1093/ofid/ofac172" @default.
• W4224302114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35493124" @default.
• W4224302114 hasPublicationYear "2022" @default.
• W4224302114 type Work @default.
• W4224302114 citedByCount "2" @default.
• W4224302114 countsByYear W42243021142023 @default.
• W4224302114 crossrefType "journal-article" @default.
• W4224302114 hasAuthorship W4224302114A5014291037 @default.
• W4224302114 hasAuthorship W4224302114A5025715364 @default.
• W4224302114 hasAuthorship W4224302114A5025877100 @default.
• W4224302114 hasAuthorship W4224302114A5032261051 @default.
• W4224302114 hasAuthorship W4224302114A5033387742 @default.
• W4224302114 hasAuthorship W4224302114A5041687666 @default.
• W4224302114 hasAuthorship W4224302114A5046856654 @default.
• W4224302114 hasAuthorship W4224302114A5047777011 @default.
• W4224302114 hasAuthorship W4224302114A5064722914 @default.
• W4224302114 hasAuthorship W4224302114A5082680257 @default.
• W4224302114 hasAuthorship W4224302114A5083402039 @default.
• W4224302114 hasBestOaLocation W42243021141 @default.
• W4224302114 hasConcept C126322002 @default.
• W4224302114 hasConcept C142724271 @default.
• W4224302114 hasConcept C168563851 @default.
• W4224302114 hasConcept C204787440 @default.
• W4224302114 hasConcept C27081682 @default.
• W4224302114 hasConcept C2778594517 @default.
• W4224302114 hasConcept C30036603 @default.
• W4224302114 hasConcept C35785553 @default.
• W4224302114 hasConcept C71924100 @default.
• W4224302114 hasConceptScore W4224302114C126322002 @default.
• W4224302114 hasConceptScore W4224302114C142724271 @default.
• W4224302114 hasConceptScore W4224302114C168563851 @default.
• W4224302114 hasConceptScore W4224302114C204787440 @default.
• W4224302114 hasConceptScore W4224302114C27081682 @default.
• W4224302114 hasConceptScore W4224302114C2778594517 @default.
• W4224302114 hasConceptScore W4224302114C30036603 @default.
• W4224302114 hasConceptScore W4224302114C35785553 @default.
• W4224302114 hasConceptScore W4224302114C71924100 @default.
• W4224302114 hasFunder F4320307758 @default.
• W4224302114 hasIssue "5" @default.
• W4224302114 hasLocation W42243021141 @default.
• W4224302114 hasLocation W42243021142 @default.
• W4224302114 hasLocation W42243021143 @default.
• W4224302114 hasOpenAccess W4224302114 @default.
• W4224302114 hasPrimaryLocation W42243021141 @default.
• W4224302114 hasRelatedWork W2026462764 @default.
• W4224302114 hasRelatedWork W2038518800 @default.
• W4224302114 hasRelatedWork W2050936608 @default.
• W4224302114 hasRelatedWork W2312635070 @default.
• W4224302114 hasRelatedWork W2766832809 @default.
• W4224302114 hasRelatedWork W2982038996 @default.
• W4224302114 hasRelatedWork W2986892476 @default.
• W4224302114 hasRelatedWork W3000734051 @default.
• W4224302114 hasRelatedWork W4256514411 @default.
• W4224302114 hasRelatedWork W4292283255 @default.
• W4224302114 hasVolume "9" @default.
• W4224302114 isParatext "false" @default.
• W4224302114 isRetracted "false" @default.
• W4224302114 workType "article" @default.